WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced its participation in the 2025 IASLC World Conference on Lung Cancer ...

Flatiron’s 2025 WCLC research showcases the power of multimodal real-world oncology data and innovative AI-data extraction methodologies to generate actionable evidence for people with lung cancer ...

The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer. Sandip Patel, MD, joined for an interview looking forward to ...

In this video, Julia Rotow, MD, discussed research highlights presented at the 2025 World Conference on Lung Cancer. "It's always hard to decide what to highlight out of a conference day at the World ...

Cullinan Therapeutics Inc. (NASDAQ:CGEM) is one of the stocks under $10 to buy now. On July 22, Taiho Oncology Inc. and Cullinan Therapeutics announced that abstracts for zipalertinib had been ...

DO-2 is a Best in Class MET kinase inhibitor that completed enrolling a Phase 1 dose escalation study. Tumour shrinkage is observed in 100% of MET exon 14 skip NSCLC patients without additional ...

CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for ...

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer Data from first ...

Editor’s Note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. It's always hard to decide what to ...

Flatiron Health today announced eight abstracts leveraging its high-quality multimodal data have been accepted for poster presentation and e-Poster presentation at the IASLC 2025 World Conference on ...